Online inquiry

IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2725MR)

This product GTTS-WQ2725MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2725MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15342MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ6975MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ETI-204
GTTS-WQ267MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ685MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ10009MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA KRN-23
GTTS-WQ11521MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ7652MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GEN-1029
GTTS-WQ347MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW